Recon: FDA finds NDMA in some metformin products; EU plans permanent medical stockpile

• “I’ll Send You the Contact”: Documents Expose FDA Commissioner’s Personal Interventions on Behalf of Trump’s Favorite Chloroquine Doctor (Vanity Fair)
• US coronavirus deaths top 100,000 as country reopens (Reuters)
• FDA Finds Carcinogen in Some Versions of Metformin (Bloomberg) (Reuters) (STAT)
• Pfizer ties up with glass maker Corning for vial supply (Reuters)
• Big gene therapy names line up behind experimental Covid-19 vaccine (STAT) (Endpoints)
• Moderna extends lipids deal to boost COVID-19 vaccine candidate output (Reuters)
• Roche mixes Actemra with Gilead's remdesivir in COVID-19 trial (Reuters) (Bloomberg) (Press)
• Gilead study shows shorter five-day course of remdesivir works as well as 10-day one (Reuters)
• Merck adopts ‘error catastrophe’ coronavirus drug (Financial Times)
• Coronavirus Continues to Disrupt Prescription Drug Supplies (NYTimes)
• Medical societies have ‘extensive’ financial ties with drug and device makers (STAT)

• EU plans permanent stockpile of essential drugs, medical gear (Reuters)
• WHO creates foundation to boost funding in coronavirus fight (Reuters) (WHO)
• AstraZeneca partners with Oxford Biomedica to expand COVID-19 vaccine manufacturing capacity (Reuters)
• AstraZeneca says it may consider exposing vaccine trial participants to virus (Reuters)
• AstraZeneca tests diabetes drug for COVID-19 despite risk seen by doctors (Reuters)
• GSK aims for one billion doses of booster as COVID-19 vaccine race heats up (Reuters)
• Indonesia to keep prescribing two malaria drugs for COVID-19 despite bans in Europe (Reuters)
• British regulator says 'COPCOV' hydroxychloroquine trial paused (Reuters)
• India allows export of paracetamol API: statement (Reuters)
• WHO Prequalifies Celltrion’s Rituximab (Pink Sheet)
• BDR Pharmaceuticals move on Remdesivir clone irks Gilead (Economic Times)

• Bad state data hides coronavirus threat as Trump pushes reopening (Politico)
• NIH director: ‘No way of knowing’ if coronavirus escaped from Wuhan lab (Politico)
• Coronavirus Epidemics Began Later Than Believed, Study Concludes (NYTimes)
• Remdesivir — An Important First Step (NEJM)
• Drugs Authorized for Coronavirus? Why There’s Skepticism (Washington Post)
• No preferential access to Themis' potential COVID-19 vaccine: CEO (Reuters)
• Pence Chief Of Staff Owns Stocks That Could Conflict With Coronavirus Response (NPR)
• Blood markers discovered for COVID-linked syndrome in children (NBC)
• Antibody Tests Were Hailed As Way To End Lockdowns. Instead, They Cause Confusion. (KHN)
• FDA offers reference panel to validate coronavirus tests amid false negative concerns (MedtechDive)
• CDC seeks to limit false positives with COVID-19 antibody testing, as immunity question lingers (MedtechDive)
• PureTech eyes clinical trial in long-term COVID-19 complications (Fierce)
• Los Angeles Authorities Sue A Company For Coronavirus-Related Fraud (NPR)
• Coronavirus (COVID-19) Update: Daily Roundup May 27, 2020 (FDA)

• LabCorp ties up with software provider to expand virtual clinical trials (Reuters)
• Medical Groups Ask FDA To Ease Access To Abortion Pill During The Pandemic (NPR)
• A CRISPR Vision for the Future of Cell Therapy (GEN)
• Stymied by the pandemic, Immunomedics' new CEO bows out, taking a million bucks plus perks as he heads out the virtual exit (Endpoints)
• US relaxes rules for opioid substitutes during lockdowns (Financial Times)
• Protalix files BLA to compete with Sanofi Genzyme; Rallybio collects another Alexion alum (Endpoints)
• Global Supply Chain In Historic Upheaval As 'De-China' Trend Marches On (Pink Sheet)
• Virtual US FDA Advisory Committees May Have One Silver Lining: Available Experts (Pink Sheet)
• Presence Of Patient Experience Data Table In FDA Drug Review Summaries ‘Inconsistent’ (Pink Sheet)
• Capitalizing Pablo: The world’s biggest drug royalty buyer is going public. And the low-key CEO divulges a few secrets along the way (Endpoints)
• Denali unveils new way of crossing blood brain barrier as the big neuroscience bet enters its clinical years (Endpoints)
• Drug developer, Big Pharma commercial exec, now an upstart biotech chief — Fabrice Chouraqui is ready to try something new as a ‘CEO-partner’ at Flagship (Endpoints)
• Thermo Fisher continues global expansion push with CSL Behring biologics plant lease (Fierce)
• Controlling Your Destiny: Why Investment in Manufacturing Capabilities Makes Sense (LifeSciVC)

• Biotronik touts results of CRT-DX study (MassDevice)
• Analysts saw 30% drop in TAVR growth in April, but Q2 may be better than feared (MedtechDive)
• Stryker announces $2.3b offering to finance Wright Medical purchase (MassDevice)
• Texas-based team seeks EUA for 3D printed emergency ventilator (MassDevice)
• Emergency authorization granted to COVID-19 ICU prediction software (MassDevice)

• Taiwan Antitrust Agency Clears Mylan, Pfizer Unit Deal (Law360)